CCR6 as a possible therapeutic target in psoriasis

Bibliography

• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352(18):1899-12
   PubMedGoogle Scholar
• Arikian SR, Einarson TR. The annual cost of psoriasis. J Am Acad Dermatol 1994;14(6):1047-8
   Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445(7130):866-73
   PubMedGoogle Scholar
• Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005;5(9):699-11
   PubMedGoogle Scholar
• Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113(12):1664-75
   PubMed Web of Science ®Google Scholar
• Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005;4(1):19-34
   PubMedGoogle Scholar
• Cua DJ, Sherlock J, Chen Y, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421(6924):744-8
   PubMedGoogle Scholar
• Murphy CA, Langrish CL, Chen Y, Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198(12):1951-7
   PubMedGoogle Scholar
• Langrish CL, Chen Y, Blumenschein WM, IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201(2):233-40
   PubMedGoogle Scholar
• Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008;128(5):1064-7
   PubMedGoogle Scholar
• Pene J, Chevalier S, Preisser L, Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180(11):7423-30
   PubMedGoogle Scholar
• Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007;19(6):652-7
   PubMedGoogle Scholar
• Wilson NJ, Boniface K, Chan JR, Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950-7
   PubMedGoogle Scholar
• Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28(4):454-67
   PubMedGoogle Scholar
• Caproni M, Antiga E, Melani L, Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29(2):210-14
   PubMedGoogle Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204(13):3183-94
   PubMedGoogle Scholar
• Duhen T, Geiger R, Jarrossay D, Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10(8):857-63
   PubMedGoogle Scholar
• Trifari S, Kaplan CD, Tran EH, Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10(8):864-71
   PubMedGoogle Scholar
• Eyerich S, Eyerich K, Pennino D, Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119(12):3573-85
   PubMedGoogle Scholar
• Nograles KE, Zaba LC, Shemer A, IL-22-producing “22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009;123(6):1244-52. e2
   PubMedGoogle Scholar
• Lee E, Trepicchio WL, Oestreicher JL, Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125-30
   PubMedGoogle Scholar
• Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006;176(3):1908-15
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13(5):715-25
   PubMed Web of Science ®Google Scholar
• Capon F, Di Meglio P, Szaub J, Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007;122(2):201-16
   PubMedGoogle Scholar
• Cargill M, Schrodi SJ, Chang M, A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80(2):273-90
   PubMedGoogle Scholar
• Nair RP, Ruether A, Stuart PE, Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128(7):1653-61
   PubMedGoogle Scholar
• Nair RP, Stuart PE, Kullavanijaya P, Genetic evidence for involvement of the IL23 pathway in Thai psoriatics. Arch Dermatol Res 2010;302(2):139-43
   Google Scholar
• Krueger GG, Langley RG, Leonardi C, A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6):580-92
   PubMedGoogle Scholar
• Leonardi CL, Kimball AB, Papp KA, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, van de Kerkhof P, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-28
   PubMedGoogle Scholar
• Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010;29(1):48-52
   PubMedGoogle Scholar
• Chan JR, Blumenschein W, Murphy E, IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203(12):2577-87
   PubMedGoogle Scholar
• Zheng Y, Danilenko DM, Valdez P, Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-51
   PubMedGoogle Scholar
• Hedrick MN, Lonsdorf AS, Shirakawa AK, CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 2009;119(8):2317-29
   PubMed Web of Science ®Google Scholar
• van der Fits L, Mourits S, Voerman JS, Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009;182(9):5836-45
   PubMedGoogle Scholar
• Szabo SK, Hammerberg C, Yoshida Y, Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: localization to both CD4+ and CD8+ subsets. J Invest Dermatol 1998;111(6):1072-8
   PubMedGoogle Scholar
• Koga T, Duan H, Urabe K, Furue M. In situ localization of IFN-gamma-positive cells in psoriatic lesional epidermis. Eur J Dermatol 2002;12(1):20-3
   PubMedGoogle Scholar
• Ortega C, Fernandez AS, Carrillo JM, IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009;86(2):435-43
   PubMedGoogle Scholar
• Teunissen MB, Koomen CW, de Waal Malefyt R, Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111(4):645-9
   PubMedGoogle Scholar
• Balato A, Unutmaz D, Gaspari AA. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J Invest Dermatol 2009;129(7):1628-42
   PubMedGoogle Scholar
• Kalish RS, Simon M, Harrington R, Skin equivalent and natural killer cells: a new model for psoriasis and GVHD. J Invest Dermatol 2009;129(3):773-6
   PubMedGoogle Scholar
• von Bubnoff D, Andres E, Hentges F, Natural killer cells in atopic and autoimmune diseases of the skin. J Allergy Clin Immunol 2010;125(1):60-8
   PubMedGoogle Scholar
• Nickoloff BJ, Wrone-Smith T, Bonish B, Porcelli SA. Response of murine and normal human skin to injection of allogeneic blood-derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 1999;135(5):546-52
   PubMedGoogle Scholar
• Nickoloff BJ, Bonish B, Huang BB, Porcelli SA. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 2000;24(3):212-25
   PubMedGoogle Scholar
• Cella M, Fuchs A, Vermi W, A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009;457(7230):722-5
   PubMedGoogle Scholar
• Satoh-Takayama N, Vosshenrich CA, Lesjean-Pottier S, Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 2008;29(6):958-70
   PubMedGoogle Scholar
• Crellin NK, Trifari S, Kaplan CD, Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010;207(2):281-90
   PubMedGoogle Scholar
• Satoh-Takayama N, Lesjean-Pottier S, Vieira P, IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010;207(2):273-80
   PubMedGoogle Scholar
• Angel CE, George E, Brooks AE, Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J Immunol 2006;176(10):5730-4
   PubMedGoogle Scholar
• Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 2007;119(5):1210-7
   PubMedGoogle Scholar
• Wollenberg A, Wagner M, Gunther S, Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119(5):1096-102
   PubMedGoogle Scholar
• Gilliet M, Conrad C, Geiges M, Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140(12):1490-5
   PubMedGoogle Scholar
• Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 1994;94(1):202-9
   PubMedGoogle Scholar
• Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129(1):79-88
   PubMedGoogle Scholar
• Bonecchi R, Galliera E, Borroni EM, Chemokines and chemokine receptors: an overview. Front Biosci 2009;14:540-51
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389(6654):978-81
   PubMedGoogle Scholar
• Annunziato F, Galli G, Cosmi L, Molecules associated with human Th1 or Th2 cells. Eur Cytokine Netw 1998;9(3 Suppl):12-6
   PubMedGoogle Scholar
• Bonecchi R, Bianchi G, Bordignon PP, Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187(1):129-34
   PubMed Web of Science ®Google Scholar
• Loetscher P, Uguccioni M, Bordoli L, CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391(6665):344-5
   PubMedGoogle Scholar
• Annunziato F, Cosmi L, Santarlasci V, Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204(8):1849-61
   PubMedGoogle Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J, Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8(6):639-46
   PubMedGoogle Scholar
• Singh SP, Zhang HH, Foley JF, Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 2008;180(1):214-21
   PubMedGoogle Scholar
• Hirota K, Yoshitomi H, Hashimoto M, Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204(12):2803-12
   PubMedGoogle Scholar
• Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol 2004;29(6):658-63
   PubMedGoogle Scholar
• Giustizieri ML, Mascia F, Frezzolini A, Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107(5):871-7
   PubMedGoogle Scholar
• Morita E, Kameyoshi Y, Hiragun T, The C-C chemokines, RANTES and eotaxin, in atopic dermatitis. Allergy 2001;56(2):194-5
   PubMedGoogle Scholar
• Raychaudhuri SP, Jiang WY, Farber EM, Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis. Acta Derm Venereol 1999;79(1):9-11
   PubMedGoogle Scholar
• Rottman JB, Smith TL, Ganley KG, Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest 2001;81(3):335-47
   PubMedGoogle Scholar
• Uchida T, Suto H, Ra C, Preferential expression of T(h)2-type chemokine and its receptor in atopic dermatitis. Int Immunol 2002;14(12):1431-8
   PubMedGoogle Scholar
• Homey B, Dieu-Nosjean MC, Wiesenborn A, Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000;164(12):6621-32
   PubMedGoogle Scholar
• Homey B, Alenius H, Muller A, CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002;8(2):157-65
   PubMedGoogle Scholar
• Kakinuma T, Saeki H, Tsunemi Y, Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J Allergy Clin Immunol 2003;111(3):592-7
   PubMedGoogle Scholar
• Gillitzer R, Ritter U, Spandau U, Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol 1996;107(5):778-82
   PubMedGoogle Scholar
• Schroder JM, Christophers E. Identification of C5ades arg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 1986;87(1):53-8
   PubMedGoogle Scholar
• Flier J, Boorsma DM, van Beek PJ, Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001;194(4):398-405
   PubMedGoogle Scholar
• Yamashita T, Akamatsu H, Tomitaka A, IP-10 in atopic dermatitis. Allergy 2003;58(3):261
   PubMedGoogle Scholar
• Fraticelli P, Sironi M, Bianchi G, Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107(9):1173-81
   PubMedGoogle Scholar
• Ong PY, Leung DY. The chemokine receptor CCR6 identifies interferon-gamma expressing T cells and is decreased in atopic dermatitis as compared with psoriasis. J Invest Dermatol 2002;119(6):1463-4
   PubMedGoogle Scholar
• Kulke R, Bornscheuer E, Schluter C, The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 1998;110(1):90-4
   PubMedGoogle Scholar
• Plant D, Young HS, Watson RE, The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol 2006;15(11):900-3
   PubMedGoogle Scholar
• DeVries ME, Cao H, Wang J, Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus. J Biol Chem 2003;278(14):11985-94
   PubMedGoogle Scholar
• Liao F, Lee HH, Farber JM. Cloning of STRL22, a new human gene encoding a G-protein-coupled receptor related to chemokine receptors and located on chromosome 6q27. Genomics 1997;40(1):175-80
   PubMedGoogle Scholar
• Greaves DR, Wang W, Dairaghi DJ, CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J Exp Med 1997;186(6):837-44
   PubMedGoogle Scholar
• Power CA, Church DJ, Meyer A, Cloning and characterization of a specific receptor for the novel CC chemokine MIP-3alpha from lung dendritic cells. J Exp Med 1997;186(6):825-35
   PubMedGoogle Scholar
• Sato K, Kawasaki H, Nagayama H, Chemokine receptor expressions and responsiveness of cord blood T cells. J Immunol 2001;166(3):1659-66
   PubMedGoogle Scholar
• Zaballos A, Varona R, Gutierrez J, Molecular cloning and RNA expression of two new human chemokine receptor-like genes. Biochem Biophys Res Commun 1996;227(3):846-53
   PubMedGoogle Scholar
• Baba M, Imai T, Nishimura M, Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997;272(23):14893-8
   PubMedGoogle Scholar
• Liao F, Rabin RL, Smith CS, CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 1999;162(1):186-94
   PubMedGoogle Scholar
• Brandes M, Legler DF, Spoerri B, Activation-dependent modulation of B lymphocyte migration to chemokines. Int Immunol 2000;12(9):1285-92
   PubMedGoogle Scholar
• Krzysiek R, Lefevre EA, Bernard J, Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells. Blood 2000;96(7):2338-45
   PubMedGoogle Scholar
• Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001;15(5):752-6
   PubMedGoogle Scholar
• Liao F, Shirakawa AK, Foley JF, Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding. J Immunol 2002;168(10):4871-80
   PubMedGoogle Scholar
• Casamayor-Palleja M, Mondiere P, Verschelde C, BCR ligation reprograms B cells for migration to the T zone and B-cell follicle sequentially. Blood 2002;99(6):1913-21
   PubMedGoogle Scholar
• Kleinewietfeld M, Puentes F, Borsellino G, CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005;105(7):2877-86
   PubMedGoogle Scholar
• Yamashiro S, Wang JM, Yang D, Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood 2000;96(12):3958-63
   PubMedGoogle Scholar
• Liao F, Alderson R, Su J, STRL22 is a receptor for the CC chemokine MIP-3alpha. Biochem Biophys Res Commun 1997;236(1):212-7
   PubMedGoogle Scholar
• Yang D, Chertov O, Bykovskaia SN, Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286(5439):525-8
   PubMedGoogle Scholar
• Soruri A, Grigat J, Forssmann U, Beta-defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol 2007;37(9):2474-86
   PubMedGoogle Scholar
• Dieu-Nosjean MC, Massacrier C, Homey B, Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000;192(5):705-18
   PubMedGoogle Scholar
• Dieu MC, Vanbervliet B, Vicari A, Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188(2):373-86
   PubMedGoogle Scholar
• Vanbervliet B, Homey B, Durand I, Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. Eur J Immunol 2002;32(1):231-42
   PubMedGoogle Scholar
• Tanaka Y, Imai T, Baba M, Selective expression of liver and activation-regulated chemokine (LARC) in intestinal epithelium in mice and humans. Eur J Immunol 1999;29(2):633-42
   PubMedGoogle Scholar
• McDonald KG, McDonough JS, Wang C, CC chemokine receptor 6 expression by B lymphocytes is essential for the development of isolated lymphoid follicles. Am J Pathol 2007;170(4):1229-40
   PubMedGoogle Scholar
• Scapini P, Laudanna C, Pinardi C, Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19. Eur J Immunol 2001;31(7):1981-8
   PubMedGoogle Scholar
• Jansen PA, Rodijk-Olthuis D, Hollox EJ, Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009;4(3):e4725
   Google Scholar
• Gambichler T, Skrygan M, Tomi NS, Differential mRNA expression of antimicrobial peptides and proteins in atopic dermatitis as compared to psoriasis vulgaris and healthy skin. Int Arch Allergy Immunol 2008;147(1):17-24
   PubMedGoogle Scholar
• Li D, Li J, Duan Y, Zhou X. Expression of LL-37, human beta defensin-2, and CCR6 mRNA in patients with psoriasis vulgaris. J Huazhong Univ Sci Technolog Med Sci 2004;24(4):404-6
   PubMedGoogle Scholar
• Huh WK, Oono T, Shirafuji Y, Dynamic alteration of human beta-defensin 2 localization from cytoplasm to intercellular space in psoriatic skin. J Mol Med 2002;80(10):678-84
   PubMedGoogle Scholar
• Clark RA, Chong B, Mirchandani N, The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006;176(7):4431-9
   PubMedGoogle Scholar
• Schmuth M, Neyer S, Rainer C, Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002;11(2):135-42
   PubMedGoogle Scholar
• Fitzhugh DJ, Naik S, Caughman SW, Hwang ST. Cutting edge: C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro. J Immunol 2000;165(12):6677-81
   PubMedGoogle Scholar
• Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008;9(6):641-9
   PubMedGoogle Scholar
• Boniface K, Bak-Jensen KS, Li Y, Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 2009;206(3):535-48
   PubMedGoogle Scholar
• Lochner M, Peduto L, Cherrier M, In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med 2008;205(6):1381-93
   PubMedGoogle Scholar
• Jandus C, Bioley G, Rivals JP, Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58(8):2307-17
   PubMedGoogle Scholar
• Danilenko DM. Review paper: preclinical models of psoriasis. Vet Pathol 2008;45(4):563-75
   PubMedGoogle Scholar
• Wolk K, Witte E, Warszawska K, The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009;39(12):3570-81
   PubMedGoogle Scholar
• Wolk K, Witte E, Wallace E, IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36(5):1309-23
   PubMedGoogle Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159(5):1092-102
   PubMedGoogle Scholar
• Boniface K, Bernard FX, Garcia M, IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174(6):3695-702
   PubMedGoogle Scholar
• Niyonsaba F, Ogawa H, Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 2004;111(3):273-81
   PubMedGoogle Scholar
• Carbone T, Nasorri F, Pennino D, CD56highCD16-CD62L- NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses. J Immunol 2010;184(2):1102-10
   PubMedGoogle Scholar
• Le Borgne M, Etchart N, Goubier A, Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity 2006;24(2):191-201
   PubMed Web of Science ®Google Scholar
• Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008;48:171-97
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 2009;19(2):199-221
   PubMed Web of Science ®Google Scholar
• Pease JE, Horuk R. Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat 2009;19(1):39-58
   PubMed Web of Science ®Google Scholar
• Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008;30(7):1228-50
   PubMedGoogle Scholar
• Sayana S, Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 2009;7(1):9-19
   PubMedGoogle Scholar
• DiPersio JF, Uy GL, Yasothan U, Kirkpatrick P. Plerixafor. Nat Rev Drug Discov 2009;8(2):105-6
   PubMedGoogle Scholar
• Fricker SP. A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs 2008;17(11):1749-60
   PubMedGoogle Scholar
• Wells TN, Power CA, Shaw JP, Proudfoot AE. Chemokine blockers – therapeutics in the making? Trends Pharmacol Sci 2006;27(1):41-7
   PubMedGoogle Scholar
• Horuk R. Promiscuous drugs as therapeutics for chemokine receptors. Expert Rev Mol Med 2009;11:e1
   Google Scholar
• Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 2010;19(3):345-55
   PubMed Web of Science ®Google Scholar
• Nishimura M, Kuboi Y, Muramoto K, Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci 2009;1173:350-6
   PubMed Web of Science ®Google Scholar
• Kalinowska A, Losy J. Investigational C-C chemokine receptor 2 antagonists for the treatment of autoimmune diseases. Expert Opin Investig Drugs 2008;17(9):1267-79
   PubMedGoogle Scholar
• Liston A, Kohler RE, Townley S, Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol 2009;182(5):3121-30
   PubMedGoogle Scholar
• Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006;97(11):1139-46
   PubMedGoogle Scholar
• Ito A, Ishida T, Yano H, Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009;58(8):1195-206
   PubMedGoogle Scholar
• Chen W, Li H, Jia Y, In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2007;28(1):30-40
   PubMedGoogle Scholar
• Jia Y, Li H, Chen W, Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther 2006;13(18):1351-9
   PubMedGoogle Scholar
• Baatar D, Olkhanud P, Newton D, CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol 2007;179(3):1996-2004
   PubMedGoogle Scholar
• Homey B, Meller S. Chemokines and other mediators as therapeutic targets in psoriasis vulgaris. Clin Dermatol 2008;26(5):539-45
   PubMedGoogle Scholar
• Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009;60(6):1001-17
   PubMedGoogle Scholar
• Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther 2009;22(5):431-40
   PubMedGoogle Scholar
• Caproni M, Antiga E, Melani L, Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29(2):210-4
   PubMedGoogle Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204(13):3183-94
   PubMedGoogle Scholar
• Gottlieb A, Menter A, Mendelsohn A, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373(9664):633-40
   PubMedGoogle Scholar
• Melis L, Vandooren B, Kruithof E, Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010;69(3):618-23
   PubMedGoogle Scholar
• Kochi Y, Okada Y, Suzuki A, A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 2010;42(6):515-9
   PubMedGoogle Scholar
• Phadke AP, Akangire G, Park SJ, The role of CC chemokine receptor 6 in host defense in a model of invasive pulmonary aspergillosis. Am J Respir Crit Care Med 2007;175(11):1165-72
   PubMedGoogle Scholar
• Ravindran R, Rusch L, Itano A, CCR6-dependent recruitment of blood phagocytes is necessary for rapid CD4 T cell responses to local bacterial infection. Proc Natl Acad Sci USA 2007;104(29):12075-80
   PubMedGoogle Scholar
• Salazar-Gonzalez RM, Niess JH, Zammit DJ, CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches. Immunity 2006;24(5):623-32
   PubMedGoogle Scholar
• Kallal LE, Schaller MA, Lindell DM, CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. Eur J Immunol 2010;40(4):1042-52
   PubMedGoogle Scholar
• Martin-Orozco N, Muranski P, Chung Y, T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31(5):787-98
   PubMedGoogle Scholar
• Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol 2010;135(3):466-75
   PubMedGoogle Scholar
• Mackay CR. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 2008;9(9):988-98
   PubMedGoogle Scholar